Quadruple therapy leads to a sustained improvement of vision in patients with wet age-related macular degeneration

Ophthalmologica

Volumn 226, Issue 2, 2011, Pages 45-50

  Koss, Michael J ^a   Lewicka Chomont, Aneta ^b   Schramm, Katharina ^a   Rejdak, Robert ^b,c   Ohrloff, Christian ^a   Koch, Frank H ^a  

^a GOETHE UNIVERSITY   (Germany)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^c MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Age related macular degeneration, wet; Choroidal neovascularization; Combined intravitreal therapy; Photodynamic therapy

Indexed keywords

BEVACIZUMAB; DEXA RATIOPHARM; DEXAMETHASONE; UNCLASSIFIED DRUG;

AGED; ARTICLE; CORTICOSTEROID THERAPY; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; RETINA MACULA AGE RELATED DEGENERATION; RETREATMENT; SUBRETINAL NEOVASCULARIZATION; VITRECTOMY;

AGED; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; PHOTOCHEMOTHERAPY; PORPHYRINS; RETINA; RETREATMENT; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY; VITRECTOMY; WET MACULAR DEGENERATION;

EID: 79955569086     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000327702     Document Type: Article

References (29)

1. Azad R, Chandra P, Gupta R: The economic implications of the use of anti-vascular endothelial growth factor drugs in age-related macular degeneration. Indian J Ophthalmol 2007; 55: 441-443.
2. Rosenfeld PJ, Rich RM, Lalwani GA: Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am 2006; 19: 361-372. (Pubitemid 44279358)
3. Korotkin A, et al: An emerging problem: Recurrence of CNV in AMD is common after cessation of 24-month treatment with ranibizumab (Lucentis). Invest Ophthalmol Vis Sci 2006; 47: ARVO E-abstract 2961.
4. Bradley J, Ju M, Robinson GS: Combination therapy for the treatment of ocular neovascularization. Angiogenesis 2007; 10: 141-148. (Pubitemid 46440632)
5. Augustin AJ, Offermann I: Combination therapy for choroidal neovascularisation. Drugs Aging 2007; 24: 979-990. (Pubitemid 350145407)
6. Spaide RF: Rationale for combination therapies for choroidal neovascularization. Am J Ophthalmol 2006; 141: 149-156. (Pubitemid 43016187)
7. Augustin AJ, Puls S, Offermann I: Triple therapy for choroidal neovascularization due to age-related macular degeneration: Verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007; 27: 133-140.
8. Barbazetto IA, Liang J, Chang S, Zheng L, Spector A, Dillon JP: Oxygen tension in the rabbit lens and vitreous before and after vitrectomy. Exp Eye Res 2004; 78: 917-924. (Pubitemid 38404284)
9. Holekamp NM, Shui YB, Beebe DC: Vitrectomy surgery increases oxygen exposure to the lens: A possible mechanism for nuclear cataract formation. Am J Ophthalmol 2005; 139: 302-310. (Pubitemid 40288276)
10. Stefansson E, Novack RL, Hatchell DL: Vitrectomy prevents retinal hypoxia in branch retinal vein occlusion. Invest Ophthalmol Vis Sci 1990; 31: 284-289. (Pubitemid 20072693)
11. Mennel S, Meyer CH, Schmidt JC: The role of the vitreous in the pathogenesis of age-related macular degeneration. Klin Monatsbl Augenheilkd 2010, E-pub ahead of print. 12 Krebs I, Brannath W, Glittenberg C, Zeiler F, Sebag J, Binder S: Posterior vitreomacular adhesion: A potential risk factor for exudative age-related macular degeneration? Am J Ophthalmol 2007; 144: 741-746.
12. Schulze S, Hoerle S, Mennel S, Kroll P: Vitreomacular traction and exudative age-related macular degeneration. Acta Ophthalmol 2008; 86: 470-481.
13. Schmidt-Erfurth U, Michels S, Barbazetto I, Laqua H: Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci 2002; 43: 830-841. (Pubitemid 34184504)
14. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials - TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Arch Ophthalmol 1999; 117: 1329-1345.
15. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001; 131: 541-560.
16. Zarbin MA: Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 2004; 122: 598-614. (Pubitemid 38456297)
17. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444. (Pubitemid 44511558)
18. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431. (Pubitemid 44511557)
19. Holz FG, Korobelnik JF, Lanzetta P, Mitchell P, Schmidt-Erfurth U, Wolf S, Markabi S, Schmidli H, Weichselberger A: The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: Outcomes of a drug and disease model. Invest Ophthalmol Vis Sci 2010; 51: 405-412.
20. Stefansson E: Physiology of vitreous surgery. Graefes Arch Clin Exp Ophthalmol 2009; 247: 147-163.
21. Stefansson E: Ocular oxygenation and the treatment of diabetic retinopathy. Surv Ophthalmol 2006; 51: 364-380. (Pubitemid 43970734)
22. Fuseya M, Imamura Y, Ishida S, Inoue M, Tsubota K: Regression of macular drusen after pars plana vitrectomy in a patient with age-related macular degeneration Retina 2007; 1: 160-162.
23. Gottsch JD, Pou S, Bynoe LA, Rosen GM: Hematogenous photosensitization: A mechanism for the development of age-related macular degeneration. Invest Ophthalmol Vis Sci 1990; 31: 1674-1682. (Pubitemid 20350888)
24. Grindle CF, Marshall J: Ageing changes in Bruch's membrane and their functional implications. Trans Ophthalmol Soc UK 1978; 98: 172-175. (Pubitemid 9098193)
25. Blair NP: Ocular oxygen consumption during vitreoperfusion in the cat. Trans Am Ophthalmol Soc 2000; 98: 305-329. (Pubitemid 32059514)
26. Wilson CA, Benner JD, Berkowitz BA, Chapman CB, Peshock RM: Transcorneal oxygenation of the preretinal vitreous. Arch Ophthalmol 1994; 112: 839-845. (Pubitemid 24180523)
27. Shima DT, Adamis AP, Ferrara N, Yeo KT, Yeo TK, Allende R, Folkman J, D'Amore PA: Hypoxic induction of endothelial cell growth factors in retinal cells: Identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med 1995; 1: 182-193.
28. Stefansson E, Landers MB 3rd, Wolbarsht ML: Vitrectomy, lensectomy, and ocular oxygenation. Retina 1982; 2: 159-166. (Pubitemid 13244957)
29. Pournaras CJ, Miller JW, Gragoudas ES, Husain D, Munoz JL, Tolentino MJ, Kuroki M, Adamis AP: Systemic hyperoxia decreases vascular endothelial growth factor gene expression in ischemic primate retina. Arch Ophthalmol 1997; 115: 1553-1558. (Pubitemid 28007138)